AI More Accurately Identifies Patients With Advanced Lung Cancer Who Respond to Immunotherapy
Researchers compared AI-powered digital scoring with traditional manual scoring of the PD-L1 immune biomarker to determine if a new immunotherapy treatment, atezolizumab, could benefit patients with advanced non-small cell lung cancer.
Study Shows Promise of Immunotherapy Treatment for Penile Cancer
An international study led by Yale Cancer Center researchers at Yale School of Medicine found that the use of immune checkpoint inhibitors offers promising clinical benefits for some patients with advanced penile squamous cell carcinoma.
Screening Mammograms Carry Risks for Older Women, Study Finds
Although some guidelines recommend continuing screening for older women, this new study emphasizes the importance of assessing potential harms associated with testing, such as overdiagnosis, which, researchers say, can negatively affect quality of life.
Taming the Self-Destructive Tendencies of Killer T Cells Used to Treat Cancer
Many engineered T cells become tainted with the remnants of cancer antigens, which causes them to turn against other T cells. This eventually depletes the body of cancer-fighting cells and opens the door for a recurrence of cancer. A new Yale study, however, has identified a way to tame the self-destructive tendencies of these killer T cells.Source: YaleNews
Combination Therapies Benefit Patients With Advanced Non-Small Cell Lung Cancer
An ongoing phase II study led by a Yale Cancer Center researcher reveals that combining pembrolizumab with other treatments reduced the size of target tumors, resulting in a higher response rate for patients with advanced NSCLC.
Pancreatic Cancer Risk Lower if Cysts Remain Stable for Five Years
Low-risk branch duct intraductal papillary mucinous neoplasms (IPMN) are the most common precancerous form of mucinous pancreatic cysts and once identified require regular surveillance imaging. But consensus is still forming around how long that watchful period should last. In a new study, Yale Cancer Center researchers question the health benefit of extended surveillance for patients whose cyst has not changed size for at least five years and has no worrisome features.
Impact of Changing Landscape for Patients With Cancer Who Are Prescribed Opioids
In response to the opioid epidemic in the United States, interventions to prevent over-prescribing and misuse of opioids were enacted at institutional, state, and federal levels. To assess how changes in the prescribing landscape affected patients, a research team from the Yale COPPER Center examined the rates of both new and persistent opioid prescribing in patients with cancer as well as in patients without cancer, utilizing data from SEER-Medicare.
Study Identifies Bereaved Parents’ Medical Priorities for Children With Advanced Cancer
For families facing the end-of-life of a loved one with pediatric cancer, robust quality measures to benchmark what parents value most in their child’s medical care do not currently exist. A new study from Yale Cancer Center helps identify what parents prioritize for their children with advanced cancer, including alleviating the child’s symptoms and honoring the family’s goals and wishes. Researchers say the findings may help establish a patient-centered agenda for quality measurement and improvement in children with advanced, incurable cancer. The study titled, "Parent Priorities in End-of-Life Care for Children with Cancer,” was published in JAMA Network Open on May 15.
Bosenberg Named Brady Professor of Dermatology, Pathology, and Immunobiology
Dr. Marcus Bosenberg, an accomplished clinician, teacher, and researcher who studies the factors that regulate anti-cancer immune responses, was recently appointed the Anthony N. Brady Professor of Dermatology, Pathology, and Immunobiology, effective immediately.Source: YaleNews
Trial Shows Significant Disease-free Survival for Patients Diagnosed With Non-small Cell Lung Cancer
The new data show there are ongoing benefits for patients taking osimertinib, including prolonged disease-free survival (DFS) over placebo, reduced risk of local and distant metastases (spread of tumor), and improved central nervous system DFS.
Older Patients Left Behind in Progress Against Lung Cancer, Yale Study Shows
Although widespread use of immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer has led to meaningful improvements in survival in younger patients, older patients have not experienced similar survival benefits, new research from Yale Cancer Center shows. The study was published in JAMA Oncology.
Yale Scientists Enable Massively Parallel DNA Insertions Into Human Cells
Yale Cancer Center scientists have developed a novel technology that for the first time enables massively parallel DNA substitutions (known as “knock-ins”) into human cells by taking advantage of messenger RNA (mRNA), a platform now well-known from its use as the COVID vaccine vehicle.